Edgewise Therapeutics Q2 EPS $(0.34) Beats $(0.40) Estimate; Cash Position Of $310M
Portfolio Pulse from Benzinga Newsdesk
Edgewise Therapeutics reported Q2 losses of $(0.34) per share, beating the analyst consensus estimate of $(0.40) by 15 percent. This represents a 5.56 percent increase over losses from the same period last year. The company's cash position stands at $310M.
August 10, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edgewise Therapeutics reported better than expected Q2 losses and an increase over losses from the same period last year. The company's strong cash position could provide stability.
Edgewise Therapeutics reported a smaller loss than expected, which is generally seen as positive by the market. Additionally, the company's strong cash position indicates financial stability, which could also be viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100